COPIKTRA

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Poland.

Active ingredients

The drug COPIKTRA contains one active pharmaceutical ingredient (API):

1	Duvelisib UNII 610V23S0JI - DUVELISIB
	Duvelisib is a dual inhibitor of phosphatidylinositol 3-kinase p110δ (PI3K-δ) and PI3K-γ. PI3K-δ inhibition directly reduces proliferation and survival of malignant B-cell lines and primary CLL tumour cells, while PI3K-γ inhibition reduces the activity of CD4+ T cells and macrophages in the tumor microenvironment to support the malignant B cells.
	Read more about Duvelisib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
COPIKTRA Capsule	MPI, US: SPL/PLR	FDA, National Drug Code (US)
COPIKTRA Hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EM04		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors
Discover more medicines within L01EM04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1849305, 1849316
FR	Base de données publique des médicaments	62881517, 69954156
IT	Agenzia del Farmaco	049523018, 049523020
LT	Valstybinė vaistų kontrolės tarnyba	1092668, 1092669
PL	Rejestru Produktów Leczniczych	100455394, 100455407
US	FDA, National Drug Code	71779-115, 71779-125